Efficacy and safety evaluation of icotinib in patients with advanced non-small cell lung cancer

Chinese Journal of Cancer Research

Volumn 25, Issue 1, 2013, Pages 90-94

  Gu, Aiqin ^a   Shi, Chunlei ^a   Xiong, Liwen ^a   Chu, Tianqing ^a   Pei, Jun ^a   Han, Baohui ^a  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

Icotinib; Non small cell lung cancer (NSCLC); Targeted therapy

Indexed keywords

ANTINEOPLASTIC AGENT; ICOTINIB; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER GROWTH; CANCER STAGING; COUGHING; DIARRHEA; DISTRESS SYNDROME; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRY SKIN; DYSPNEA; FATIGUE; FEMALE; HUMAN; INTERSTITIAL PNEUMONIA; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MOUTH ULCER; PARONYCHIA; POINT MUTATION; QUALITY OF LIFE; SIDE EFFECT; SMOKING; SYMPTOM; THORAX PAIN; TREATMENT RESPONSE; WILD TYPE;

EID: 84875287807     PISSN: 10009604     EISSN: 19930631     Source Type: Journal    
DOI: 10.3978/j.issn.1000-9604.2012.12.07     Document Type: Article

References (25)

1. Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin 2011;61:69-90.
2. Méndez M, Custodio A, Provencio M. New molecular targeted therapies for advanced non-small-cell lung cancer. J Thorac Dis 2011;3:30-56.
3. Ramalingam S, Belani C. Systemic chemotherapy for advanced non-small cell lung cancer: recent advances and future directions. Oncologist 2008;13:5-13.
4. Huang SM, Harari PM. Epidermal growth factor receptor inhibition in cancer therapy: biology, rationale and preliminary clinical results. Invest New Drugs 1999;17:259-69. (Pubitemid 30037958)
5. Metro G, Finocchiaro G, Toschi L, et al. Epidermal growth factor receptor (EGFR) targeted therapies in non-small cell lung cancer (NSCLC). Rev Recent Clin Trials 2006;1:1-13.
6. Enting D, Spicer J. EGFR inhibition and more: a new generation growing up. J Thorac Dis 2012;4:553-5.
7. Pao W, Miller V, Zakowski M, et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A 2004;101:13306-11. (Pubitemid 39209661)
8. Mendelsohn J, Baselga J. Epidermal growth factor receptor targeting in cancer. Semin Oncol 2006;33:369-85. (Pubitemid 44142736)
9. Metro G, Crinò L. Advances on EGFR mutation for lung cancer. Transl Lung Cancer Res 2012;1:5-13.
10. Chou T, Finn RS, Garon EB. Expanding options for EGFR targeting in lung cancer. Transl Lung Cancer Res 2012;1:287-8.
11. Pennell NA. Treating acquired resistance to EGFRtyrosine kinase inhibitors: Still a work in progress. Transl Lung Cancer Res 2012;1:149-51.
12. Han SW, Hwang PG, Chung DH, et al. Epidermal growth factor receptor (EGFR) downstream molecules as response predictive markers for gefitinib (Iressa, ZD1839) in chemotherapy-resistant non-small cell lung cancer. Int J Cancer 2005;113:109-15.
13. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005;353:123-32. (Pubitemid 41058344)
14. Sun Y, Shi Y, Zhang L, et al. A randomized, double-blind phase III study of icotinib versus gefitinib in patients with advanced non-small cell lung cancer (NSCLC) previously treated with chemotherapy (ICOGEN). J Clin Oncol 2011;29:abstr 7522.
15. Normanno N, Bianco C, De Luca A, et al. Target-based agents against ErbB receptors and their ligands: a novel approach to cancer treatment. Endocr Relat Cancer 2003;10:1-21. (Pubitemid 36457237)
16. Salomon DS, Brandt R, Ciardiello F, et al. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 1995;19:183-232.
17. Fontanini G, De Laurentiis M, Vignati S, et al. Evaluation of epidermal growth factor-related growth factors and receptors and of neoangiogenesis in completely resected stage I-IIIA non-small-cell lung cancer: amphiregulin and microvessel count are independent prognostic indicators of survival. Clin Cancer Res 1998;4:241-9. (Pubitemid 28062903)
18. Kim ES, Hirsh V, Mok T, et al. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. Lancet 2008;372:1809-18.
19. Tassinari D, Carloni F, Santelmo C,et al. Second line treatments in advanced platinum-resistant non small cell lung cancer. A critical review of literature. Rev Recent Clin Trials 2009;4:27-33.
20. Tan F, Shen X, Wang D, et al. Icotinib (BPI-2009H), a novel EGFR tyrosine kinase inhibitor, displays potent efficacy in preclinical studies. Lung Cancer 2012;76:177-82.
21. Tan FL, Zhang L, Zhao Q, et al. Pharmacology and clinical evaluation of Icotinib Hydrochloride. Chinese Journal of New Drugs 2009;18:1691-700.
22. Zhao Q, Shentu J, Xu N, et al. Phase I study of icotinib hydrochloride (BPI-2009H), an oral EGFR tyrosine kinase inhibitor, in patients with advanced NSCLC and other solid tumors. Lung Cancer 2011;73:195-202.
23. Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009;361:947-57.
24. Maemondo M, Inoue A, Kobayashi K, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010;362:2380-8.
25. Zhou C, Wu YL, Chen G, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 2011;12:735-42.